Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422992 · ClinicalTrials.gov registry record
Haptoglobin and Iron in Parkinson's Disease
A clinical trial of Parkinson's Disease, sponsored by Bastyr University.
- Completed
- Registry status
- 342
- Enrollment target
- 3
- Study locations
NCT02422992: Completed study of Parkinson's Disease, sponsored by Bastyr University.
NCT02422992 is a study of Parkinson's Disease that has completed, run by Bastyr University. The registered enrollment target is 342 participants, below the 633-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (46% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02422992, a study of Parkinson's Disease, has completed, sponsored by Bastyr University.
- COMPLETED
- Registry status
- 342 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a case/control epidemiology study to identify what are the iron-metabolism abnormalities in Parkinson's disease (PD) patients, and risk factors relevant to PD predisposition.
Primary Outcome
Iron metabolism will be measured by testing for serum iron and iron-binding proteins, and by estimating brain iron by MRI. Serum iron parameters that will be measured include total serum iron, iron-binding proteins such as transferrin and ferritin, and tests related to iron metabolism: transferrin % saturation, unsaturated iron binding capacity, soluble transferrin receptor, complete blood count, hemoglobin, uric acid, haptoglobin, haptoglobin phenotype. Differences in serum iron parameters, and
Conditions Studied
Study Locations (3)
Washington
- Bastyr University Research Institute - Kenmore
- University of Washington - Seattle
California
- University of California - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-06 |
What the finished NCT02422992 record still lists
NCT02422992 is an observational study that tracks outcomes without assigning an intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, below the 633-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02422992 reports a single indexed study location in Washington, California.
Frequently Asked Questions
What is clinical trial NCT02422992 about?
NCT02422992 is a clinical study titled "Haptoglobin and Iron in Parkinson's Disease". This is a case/control epidemiology study to identify what are the iron-metabolism abnormalities in Parkinson's disease (PD) patients, and risk factors relevant to PD predisposition.
What is the current status of trial NCT02422992?
This trial is currently completed. The enrollment target is 342 participants. The study started on 2013-02. Estimated completion is 2016-06.
What conditions does trial NCT02422992 study?
This clinical trial studies the following conditions: Parkinson's Disease.
Who is sponsoring clinical trial NCT02422992?
This trial is sponsored by Bastyr University, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02422992 being conducted?
This trial has 3 study locations across California, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02422992's enrollment target sits among peer trials
342 22nd of 158 higher than 137 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia